Exploring the Potential Role of GLP1-RAs in Treating Obesity-Related Cancers

The convergence of obesity, metabolic dysregulation, and cancer outcomes creates a compelling rationale to explore GLP-1RAs as a potential adjuvant, therapeutic, or preventative pharmacologic intervention, particularly for obesity-related cancers. Real-world evidence from large clinical databases offers a timely opportunity to assess some associations, but prospective research is critically needed to establish the long-term safety and efficacy, as well as the effects on cancer risk and outcomes.